` COYA (Coya Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

C
COYA
vs
S&P 500

Over the past 12 months, COYA has underperformed S&P 500, delivering a return of +6% compared to the S&P 500's +15% growth.

Stocks Performance
COYA vs S&P 500

Loading
COYA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
COYA vs S&P 500

Loading
COYA
S&P 500
Difference
www.alphaspread.com

Performance By Year
COYA vs S&P 500

Loading
COYA
S&P 500
Add Stock

Competitors Performance
Coya Therapeutics Inc vs Peers

S&P 500
COYA
ABBV
AMGN
GILD
VRTX
Add Stock

Coya Therapeutics Inc
Glance View

Market Cap
100.5m USD
Industry
Biotechnology

Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company is headquartered in Houston, Texas. The company went IPO on 2022-12-29. The firm is focused on developing new therapies to enhance the function of regulatory T cells (Tregs). The company is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. The company has a diversified product candidate pipeline that includes both ex vivo (outside the body) and in vivo (inside the body) therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Its 300 Series product candidates include COYA 301 and COYA 302, its 200 Series product candidates include COYA 201 and COYA 206, and its 100 Series product candidate is COYA 101. Its COYA 301 is a biologic for subcutaneous administration. Its COYA 302 is a combination of two molecules for subcutaneous and/or intravenous administration. Its COYA 201 product candidate utilizes its Treg-derived exosome therapeutic modality. Its COYA 101 is its autologous regulatory T-cell product candidate.

COYA Intrinsic Value
4.34 USD
Overvaluation 28%
Intrinsic Value
Price
C
Back to Top